Osteoarthritis (OA) is a progressive degradation disease of cartilage resulting in substantial pain and functional limitations.
This new form of treatment has been developed to concentrate both crucial growth factors and antagonists of inflammatory mediators within the body with promising preliminary results and clinical outcomes, Especially in terms of safety profile and clinical improvement. The purpose of this particular study was to investigate if one single joint injection of autologous (self) protein solution (APS) can reduce pain and improve function in patients affected by knee arthritis in a multicenter, randomized, double-blind, saline-controlled study.
Imaging evaluation was also performed with radiograph and magnetic resonance imaging (MRI) before and after treatment. Results found The safety was positive, with no significant differences in frequency and severity of adverse events between. At 12 months, improvement in pain reduction score was 65% in the APS tretment group. Significant differences between groups were detected in change from baseline to 12 months in bone marrow lesion size as assessed on MRI and osteo spurring in the thigh bone, both in favor of the APS group.
Conclusion: This study provides evidence to support the safety and clinical improvement at 1-year follow-up of a single joint injection of APS in patients affected by knee OA. Treatment with APS or a saline injection provided significant pain relief over the course of the study with differences becoming apparent at between 6 and 12 months after treatment.
Find out more: